A recent study indicated that DDR‐related ATM or BRCA2 somatic mutations are promising biomarkers for assessing the response of stage III CRC patients to oxaliplatin‐based chemotherapy.16 This evidence concerns the gene BRCA2 and colorectal carcinoma.